tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Posts Tagged 'JDRF'

Johnson & Johnson and Big Pharma Could Find a Diabetes “Cure” with PharmaCyte Biotech’s Type 1 Diabetes Treatment

Johnson & Johnson and Big Pharma Could Find a Diabetes “Cure” with PharmaCyte Biotech’s Type 1 Diabetes Treatment

Written by Ι Stock Market Media — February 8, 2016

Johnson & Johnson, like much of the biopharmaceutical industry worldwide, is aware of the desperate necessity for a Type 1 diabetes treatment. In fact, Diego Miralles, Johnson & Johnson’s head of global innovation, said that his company’s recent decision to partner with a privately held San Diego biotech was to “hedge our bets to make sure we would win in this space.” Johnson & Johnson’s deal with ViaCyte, Inc. is an effort to ...

Read More →
0

PharmaCyte Biotech Outlines 2016 Milestones as Company Moves Into Cancer Clinical Trial

PharmaCyte Biotech Outlines 2016 Milestones as Company Moves Into Cancer Clinical Trial

SILVER SPRING, Md., Jan. 06, 2016 — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the Company’s 2016 milestones as it advances its new treatment for pancreatic cancer into the clinic in the United States with study sites in Europe and Australia.

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We are excited to see 2016 ...

Read More →
0

Nuvilex Eyeing Partnership for Its Share of Future $114 Billion Diabetes Market

Nuvilex Eyeing Partnership for Its Share of Future $114 Billion Diabetes Market

Written by ι Stock Market Media Group Staff — July 7, 2014

Nuvilex, Inc. (OTCQB: NVLX) announced last week that its executives recently met with the company’s “global development partners” at the 2014 BIO International Convention in San Diego.  One of the meetings that CEO Ken Waggoner and COO Dr. Gerald Crabtree held was with a representative of the Juvenile Diabetes Research Foundation (JDRF) to discuss Nuvilex’s plans for treating diabetes.  This, of course, begs the question − is Nuvilex in line for ...

Read More →
0
ContactUs.com